Member Info for Greg25

Nope, they're just part of the 430M extra shares from drawdown, being flipped. Around 50M have been churned so far, which means most of the holders are waiting/expecting a higher share price.

Looking forward to seeing how this all pans out here

Good call, I'm going for 50 BOPD.!

Good Luck All Shareholders

Hi Guys,

BTN-14 well workover completion is imminent now, they'll be generating revenues from the off.

All the infrastructure is in place and working.

Looking forward to hearing the updates and bopd increase.

Exciting times ahead here.

I am a shareholder here. I will buy more shares too.
All I'm saying is this share will retrace as we wait for some tangible news as ramping does have a finite number of new investors before they start asking serious questions like the difference in size of the trade sells compared to the buy sells. One might say new investors will be rinsed as we wait.

Hi Guys,

The podcast said 12 days for completion of workover at BTN-14.

The video of the service rig at BTN-14, was from 7/8 days s ago.

Wednesday coming, BTN-14 Should be on-stream, with all the infrastructure already in place, Oil can be pumped straight to market, Generating instant revenues.

Exciting times ahead here.

Hi Guys,

"The announcement of the final read-out of our Phase 2 trial of SFX-01 in subarachnoid haemorrhage remains in line with earlier guidance of Q3 or early Q4 of this calendar year"

I expect the share price to rise into these transformational results:

"We are excited by the outcome of this blinded study in an indication where there has been no significant clinical advance in more than 20 years."

They will be generating revenues soon afterwards, as per orphan drug status.

Good Luck All Shareholders

Hi Guys,

ADL has stated:

"ADL recovers its DD investment via incremental production from Betun"

”On successful completion of due diligence programme ADL will execute SPA
and commence full field development"

Even if they just carry out what they have promised, their revenues would be around £9.6M for the remainder of the kSO.

With a company with £1M- 2M MCAP I'm happy to hold here.

Good Luck All Shareholders

The US Food & Drug Administration (“FDA”) has granted Evgen orphan drug designation for the use of stabilised sulforaphane for the treatment of subarachnoid haemorrhage.

Meaning;

Evgen can sell the drug, after releasing phase II results, Generating vast revenues whilst carrying out phase III on both STEM & SAH trials.

Good Luck All Shareholders only weeks away now

"if the results are positive, people will see the potency of the molecule relative to a drug doing US$5bn a year"

later today. At the AGM, the Company's Chairman, Barry Clare, will make the following statement.

"We continue to make significant progress in establishing Evgen as a world leader in sulforaphane-based pharmaceuticals.

"In March this year we announced that our lead product, SFX-01, had met its primary endpoints in an open label Phase 2 trial of SFX-01 in metastatic breast cancer. The trial data confirmed that SFX-01 is a highly promising anti-cancer agent with an excellent tolerability profile."

"The announcement of the final read-out of our Phase 2 trial of SFX-01 in subarachnoid haemorrhage remains in line with earlier guidance of Q3 or early Q4 of this calendar year. "

"We are excited by the outcome of this blinded study in an indication where there has been no significant clinical advance in more than 20 years."

Exciting times ahead here.

Hi Guys,

With the extra shares , now live and not in public hands.

The float is a reportedly 327.73M (31.5%)

https://uk.finance.yahoo.com/quote/ADL.L/key-statistics?p=ADL.L

Exciting times ahead here.

Hi Guys,

The float is reportedly : 327.73M (31.5%)

Looking forward to updates on workover and more.

Exciting times ahead here.

Hi Guys,

"On average, they anticipate Evgen Pharma's stock price to reach GBX 74 in the next twelve months. This suggests a possible upside of 322.9% from the stock's current price."

Going to be under 3 months, most likely to be taken over thereafter.

Exciting times ahead here.

Hi Guys,

That's the first RNS, part of the original £500k drawdown, there will be more to come as they have previously stated that the 6.5% taken for second drawdown was from an existing shareholder.

It's good news for shareholders, as the new TR-1 holders are unlikely to flip their shares short term.

Workover in progress, we should have updates throughout the process as ADL will actually be producing oil & revenues, in around a week's time.

Exciting times ahead here

Hi Guys,

Big position being taken here.!

Looking forward to the next trading update.

Hi Radar,

Yes, that's more to do with how the market works and less to do with the share itself.

The money doesn't wait around, it moves to the next best thing and returns for the results. It has a real fear of missing out.

AGM this week, after that there will be a return of investors, building up to the results news and more.

The SAH trial , for SFX-01, is the quickest route to market (Revenues) for Evgen Pharma.( Through orphan drug status)

They took the decision, not to release the primary endpoint data, for good reason. Numbers speak for themselves, so the results must be good to exceptional, to be able to maximize commercial value.

Exciting times ahead here.

Hi Guys,

Barry Clare, non ex-chairman:

"As the former Managing Director of Boots Healthcare International, he led the global expansion of a leading portfolio of brands including Nurofen, Strepsils and Clearasil"

He holds £164.5k worth of Evgen shares and knows very well, the $5 Billion potential for SFX-01 (Sulforaphane)

Phase II SAS trial , primary & secondary endpoint results are to be released at the same time, to maximize commercial value.

After the results release, Evgen Pharma will be able to make deals , with multiple pharma's as they will be able to draw an income from the sales of SFX-01 (Orphan Drug Status) as they work towards Phase III.

Exciting times ahead here.

Hi Guys,

Evgen Pharma is in a prime position as we're in the remaining weeks, until the SFX-01 Phase 2 SAS trial results are revealed. Evgen Pharma will once again become the focus of the Big Pharmaceutical companies. (As they were pre-IPO, when the first offer was made)

Gaining orphan designation has allowed SFX-01 to go on sale after the completion of Phase II trials if the drug proved efficacious and a Conditional Market Approval is gained.

It would still have to complete the final leg of clinical studies, but could be earning income at the same time.

The patent covers the manufacturing process of SFX-01 – a synthetic version of the naturally occurring compound sulforaphane – and runs until 2033.

“This patent grant extends our intellectual property protection in the world's largest pharmaceutical market and is the first of a potentially broad geographical spread of patents that are pending in Europe, Japan, India, China, Canada, Brazil and Australia,” said chief executive Stephen Franklin.

Under the terms of the licence agreement with PharmAgra Labs Inc – the US lab which invented the compound – Evgen holds the exclusive worldwide rights to the patent.

Exciting times ahead here

Good Luck All Shareholders

Hi Guys,

I'd like to see the next video, to be the BTN 14 Pump Jack in operation, knowing that every stroke is generating revenues for ADL.

Exciting times ahead :)

Hi Guys,

How the KSO works, the 70bopd is probably the Indonesian Govt cut in the oil operations there.

Any increase in bopd would be area for profit margin, for the operator (s).

The last 3 years, the bopd at Betun, was above the promised 150bopd. There may have also been upto 6 wells producing oil.

It's a 4 well workover and a 9month "Proof of Concept"

During the concept stage, the other two oils wells mentioned in the title, are highly likely to be investigated further. (For increased revenue /production)

Selo field for Gas, this is part 2 of the next stage. Most likely to be the largest revenue stream in the future, from Betun-Selo.

" Some 33 bcf of gas available for commercialization in an area urgently requiring gas"

The Indonesian Govt, is offering a 10-20% bigger incentive for operator's to produce Gas.

ADL's lucrative angle of working/operating for the KSO, circumvents most of the pitfalls that have been so costly before.

The opportunity to have CAV as a co-investor/ partner will truly be very lucrative for ADL, in this and future projects.

Good Luck All Shareholders

Exciting times ahead here

Hi Guys,

"Big pharma companies are very interested in SFX-01 and one even tried to buy Evgen shortly before it was floated back in December 2015.

But Franklin and his team want to deliver Phase II data on both breast cancer and SAH before concluding a licensing deal or deals."

All indications are good , they have orphan drug status, SFX-01 can go on sale after phase 2 trials completed. (End of Summer 2019)

Primary and secondary results will be unblinded together, to maximize commercial value.

Exciting times ahead here.